文献速递肾移植

达雷妥尤单抗用于肾移植前脱敏的开放标签1/2期研究

Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation.
PubMed 文献 · Kidney Int Rep · 2024-08-26

该研究在cPRA>95%的肾移植等待者中评估达雷妥尤单抗脱敏的6个月安全性和有效性。1期采用4周递增剂量,2期采用8周每周16 mg/kg方案。结果显示输注相关不良事件为主,抗HLA抗体在3个月时显著下降但12个月完全回归基线,持久应答者不足40%,限制其临床应用。

要点

  • 达雷妥尤单抗脱敏主要不良事件为1-2级输注相关反应,无严重治疗相关不良事件。
  • 抗HLA抗体在3个月时显著下降,但12个月时完全回归基线水平。
  • 6个月时cPRA 10000持续应答率76.92%,cPRA 2000持续应答率46.15%,持久应答者不足40%。

核心结论

  • 达雷妥尤单抗脱敏可快速但短暂降低抗HLA抗体,持久应答者不足40%,限制其临床潜在应用。

研究设计与样本

  • 单中心开放标签1/2期研究,纳入cPRA>95%的肾移植等待者,1期9例采用4周递增剂量,2期14例采用8周每周16 mg/kg达雷妥尤单抗。

主要发现

  • 安全性分析显示4例严重非治疗 emergent 不良事件、36例轻度治疗 emergent 不良事件(多为1-2级输注相关反应,导致2例暂时停药),无严重治疗 emergent 不良事件。
  • 3个月时抗HLA抗体显著下降:cPRA 10000(P=0.003)、抗HLA数量(P<0.001)、最大MFI(P=0.053)、MFI总和(P<0.001),12个月时完全回归基线。
  • 6个月时cPRA 2000和cPRA 10000的持续应答率(cPRA下降1%)分别为46.15%(19.22%-74.87%)和76.92%(46.19%-94.96%)。
  • 1个月时免疫细胞(T-reg、CD8+ TEMRA、CD19+CD138+ B细胞和NK细胞)显著下降;3个月时其他抗体显著下降,12个月时除丙种球蛋白外均回归基线,无感染并发症。

临床怎么用

  • 达雷妥尤单抗脱敏的抗体下降短暂且持久应答率低,临床使用需谨慎评估获益与风险。

局限性

  • 单中心开放标签设计,样本量小(1期9例、2期14例),持久应答率低限制其临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The safety and benefit of the anti-CD38 monoclonal antibody daratumumab, which induces lysis of antibody-producing plasma cells in sensitized patients prior to kidney transplantation, remain to be determined. METHODS: A 2-phase (1 and 2), monocentric open-label study was conducted to evaluate the month 6 (M6) safety and efficacy of daratumumab in kidney transplant candidates with calculated panel reactive antibody (cPRA) > 95%. In the first (safety) phase, we used 4-weekly escalating doses of daratumumab. Phase 2 tested desensitization with 8 weekly infusions of 16 mg/kg daratumumab. cPRA 10,000 was calculated considering only human leukocyte antigen (HLA) antibodies with mean fluorescence intensity (MFI) of > 10,000. RESULTS: Nine patients were enrolled in phase 1 and 14 in phase 2. Safety analysis showed 4 serious non-treatment-emergent adverse events (non-TEAEs), 36 mild TEAEs, mostly infusion-related reactions, grade 1 and 2 (causing 2 temporary drug discontinuations), but no serious TEAEs. Significant reductions in anti-HLA antibodies were observed at month 3 (M3), with cPRA 10,000 (P = 0.003), number of anti-HLA (P < 0.001), maximum MFI (MFI max) (P = 0.053), and the sum of MFI (MFI sum) (P < 0.001), with complete return to baseline levels at month 12 (M12). At M6, 46.15% (19.22%-74.87%) and 76.92% (46.19%-94.96%) of patients showed sustained response (1% decrease in cPRA) for cPRA 2000 and 10,000, respectively. At month 1 (M1), immune cells (T-reg, CD8 + TEMRA, CD19 + CD138 + B cells, and NK cells) significantly decreased. At M3, other antibodies decreased significantly, but returned to baseline levels at M12, except for gamma globulins, without any infectious complications. CONCLUSION: The first use of daratumumab in desensitization demonstrated infusion-related adverse (AEs) events and rapid, albeit transient, reductions in anti-HLA antibodies, with less than 40% of durable responders, limiting its potential clinical use.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Pilon C, Joher N, Usureau C, et al. Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation. Kidney Int Rep. 2024. PMID: 39534185. doi:10.1016/j.ekir.2024.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。